( 1 of 2 ) |
United States Patent | 7,015,008 |
Shou , et al. | March 21, 2006 |
The present invention features antibodies referred to herein as "MAb50-4" and "MAb184-10", and polypeptides that compete with MAb50-4 and MAb184-10 for binding to CYP2D6. MAb50-4 can be produced by ATCC No. PTA-3489, while MAb184-10 can be produced by ATCC No. PTA-1999.
Application Number | Filing Date | Patent Number | Issue Date | ||
60236665 | Sep., 2000 | ||||
Current U.S. Class: | 435/7.4 ; 435/18; 435/338; 530/388.26 |
Current International Class: | C07K 16/40 (20060101); C12N 5/20 (20060101); G01N 33/573 (20060101) |
Field of Search: | 435/7.4,18,338 530/388.26 |
5693762 | December 1997 | Queen et al. |
5830667 | November 1998 | Alvarez et al. |
6054297 | April 2000 | Carter et al. |
6056957 | May 2000 | Chou et al. |
6060253 | May 2000 | Gelboin et al. |
6060353 | May 2000 | Koh et al. |
WO 95/17516 | Jun., 1995 | WO | |||
WO 00/04861 | Feb., 2000 | WO | |||
WO 00/04864 | Feb., 2000 | WO | |||
Coon, M. et al. "Cytochrome P450: progress and predictions", FASEB, 1992, vol. 6, pp. 669-673. cited by other . Gelboin, H. et al. "A monoclonal antibody inhibitory to human P450 2D6: a paradigm for use in combinatorial determination of individual P450 role in specific drug tissue metabolism", Pharmacogenetics, 1997, vol. 7, pp. 469-477. cited by other . Gelboin, H. et al. "Inhibitory and Noninhibitory Monoclonal Antibodies to Human Cytochrome P450 2E1", Chem. Res. Toxicol., 1996, vol. 9, pp. 1023-1030. cited by other . Gelboin, H. et al. "Inhibitory and Noninhibitory Monoclonal Antibodies to Human Cytochrome P450 3A3/4", Biochemical Pharmacology, 1995, vol. 50, pp. 1841-1850. cited by other . Gonzalez, F. "The Molecular Biology of Cytochrome P450s", Pharmacological Reviews, 1989, vol. 40, pp. 243-288. cited by other . Guengerich, F. et al. "Cytochrome P-450 Oxidations and the Generation of Biologically Reactive Intermediates", Advances in Experimental Medicine and Biology, 1991, vol. 283, pp. 1-11. cited by other . Guengerich, F. "Metabolic Activation of Carcinogens", Pharmac. Ther., 1992, vol. 54, pp. 17-61. cited by other . Krausz, K. et al. "Inhibitory Monoclonal Antibodies to Human Cytochrome P450 2D6", Biochemical Pharmacology, 1997, vol. 54, pp. 15-17. cited by other . Mei, Q. et al. "Role of a Potent Inhibitory Monoclonal Antibody to Cytochrome P-450 3A4 in Assessment of Human Drug Metabolism", The Journal of Pharmacology and Experimental Therapeutics, 1999, vol. 291, pp. 749-759. cited by other . Nelson, D. et al. "P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature", Pharmacogenetics, 1996, vol. 6, pp. 1-42. cited by other . Ngui, J. et al. "Cytochrome P450 3A4-Mediated Interaction of Diclofenac and Quinidine", Drug Metabolism and Disposition, 2000, vol. 28, pp. 1043-1050. cited by other . Shou, M. et al. "Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivaties: enzyme specificity, interindividual distribution and metabolic contribution in human liver", Pharmacogenetics, 1998, vol. 8, pp. 391-401. cited by other . Shou, M. et al. "Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone", Carcinogenesis, 1997, vol. 18, pp. 207-214. cited by other . Shou, M. et al. "Sigmoidal kinetic model for two co-operative substrate- binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives", Biochem J., 1999, vol. 340, pp. 845-853. cited by other . Shou, M. et al. "Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 to human drug metabolism", European Journal of Pharmacology, 2000, vol. 394, pp. 199-209. cited by other . Tang, C. et al. "Major Role of Human Liver Microsomal Cytochrome P450 2C9 (CYP2C9) in the Oxidative Metabolism of Celecoxib, Novel Cyclooxgenase-II Inhibitor", The Journal of Pharmacology and Experimental Therapeutics, 2000, vol. 293, p. 453-459. cited by other . Tang, C. et al. "Substrate-Dependent Effect of Acetonitrile on Human Liver Microsomal Cytochrome P450 2C9 (CYP2C9) Activity", Drug Metabolism and Disposition, 2000, vol. 28, pp. 567-572. cited by other . Yang, T. et al. "Inhibitory Monoclonal Antibody to Human Cytochrome P450 2B6", Biochemical Pharmacology, 1998, vol. 55, pp. 1633-1640. cited by other . Shou, M. et al. "Two Inhibitory Monoclonal Antibodies Against Human CYP2D6", Drug Metabolism Reviews, 2000, vol. 32, p 211, abstract No. 149. cited by other . Gelboin, H. et al. "Inhibitory monoclonal antibodies to human cytochrome P450 enzymes: a new avenue for drug discovery", Trends in Pharmacological Sciences, 1999, vol. 20, pp. 432-438. cited by other . Klein, R. et al. "Overlapping but distinct specificities of anti-liver-kidney microsome antibodies in autoimmune hepatitis type II and hepatitis C revealed by recombinant native CYP2D6 and novel peptide epitopes", Clinical and Experimental Immunology, 1999, vol. 118, pp. 290-297. cited by other . Engel, G. et al. "Prediction of CYP2D6-mediated polymorphic drug metablolism (sparteine type) based on in virto investigations", Journal of Chromatography, 1996, vol. 678, pp. 93-103. cited by other. |